glp 1 drug interactions GLP-1 Agonist-Induced Delayed Gastric Emptying – A Clinical Pharmacology Perspective GLP-1 Receptor Agonists Drug-Drug Interaction

Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes

In 2025 we saw label expansions for semaglutide and tirzepatide, underscoring a trend toward whole-body health

Liraglutide (3.0 mg, daily subcutaneous injection, n=22) or semaglutide (1.0 mg, weekly subcutaneous injection, n=18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%

It plays several important roles: Helping maintain healthy blood sugar levels after meals Supporting a feeling of fullness and satisfaction Regulating appetite and digestion When GLP-1 activity is healthy, it may help reduce cravings, support balanced energy, and contribute to gradual, sustainable weight management

Retatrutide reported up to 28.7% average weight loss and pain reduction of up to 75.8% on the WOMAC scale in adults with obesity and knee osteoarthritis [9]